Salmeterol Xinafoate Articles
Forest launches COPD product Tudorza in USA
12 December 2012
Retail drug sales in year to March 2009
22 May 2009
Retail drug sales in year to February 2009
24 April 2009
Retail drug sales in year to January 2009
3 April 2009
Retail drug sales in year to December 2008
30 March 2009
Japan stock market week to Feb 23, 2009
2 March 2009
Retail drug sales in year to November 2008
26 January 2009
Retail drug sales in year to October 2008
22 December 2008
Retail drug sales in year to September 2008
17 November 2008
Retail drug sales in year to August 2008
20 October 2008
Retail drug sales in year to July 2008
22 September 2008
Retail drug sales in year to June 2008
18 August 2008
Retail drug sales in year to May 2008
4 August 2008
Retail drug sales in year to April 2008
28 July 2008
Retail drug sales in year to March 2008
16 June 2008
Retail drug sales in year to February 2008
19 May 2008
Retail drug sales in year to January 2008
21 April 2008
GSK's asthma drugs not impacted by genetic profiles
24 March 2008
Drug sales up 5% in year to August 2007
22 October 2007
Drug sales up 5% in year to July 2007
24 September 2007
Retail drug sales up 5% in 2005
10 April 2006
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
Schwarz forecasts two-fold earnings growth in 2003
3 March 2003
Update - GSK shares hit as Serevent safety trial is halted
3 February 2003
GSK halts Serevent trial; FDA backs product
3 February 2003
Stock Commentary - Week to January 27 - Europe
3 February 2003
HIV/AIDS therapy sales forecasts to 2009
3 August 2000
GW gains first approval for Seretide MDI
20 June 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
GW files for European approval of Seretide MDI
16 December 1999
Stock Commentary Europe
2 December 1999
Japan gives provisional backing to GW's Relenza, Canada OKs Advair
29 November 1999
GW files first dossiers for Flixotide in COPD
10 May 1999
GW gets FDA extension in Relenza review
8 April 1999
Canada approve GW's Serevent
23 February 1999
GW Files For Approval Of Seretide Combo
30 April 1998
Serevent Diskus Licensed In USA
25 September 1997
Glaxo Wellcome 1996 Product Performance
17 March 1997
Glaxo Wellcome Reveals Integration Effects
11 September 1995
Allen & Hanbury's Accuhaler
22 May 1995
Glaxo Interim Profits Up 10% On 2% Sales Rise
13 February 1995
BAXTER DONATION
8 August 1994
US LAUNCH FOR GLAXO'S SEREVENT
11 April 1994
GLAXO'S SEREVENT GAINS US APPROVAL
14 February 1994
SEREVENT GAINS CHILD ASTHMA INDICATION
8 February 1993
CHANGING FACE OF THE ASTHMA MARKET
9 March 1992
PRODUCT APPROVALS FOR GLAXO
27 January 1992
Showing 1-54 of 54 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
